Cryptogenic organizing pneumonia medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Cryptogenic organizing pneumonia}} | {{Cryptogenic organizing pneumonia}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}} {{MKK}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:26, 27 February 2018
|
Cryptogenic Organizing Pneumonia Microchapters |
|
Differentiating Cryptogenic organizing pneumonia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cryptogenic organizing pneumonia medical therapy On the Web |
|
American Roentgen Ray Society Images of Cryptogenic organizing pneumonia medical therapy |
|
Cryptogenic organizing pneumonia medical therapy in the news |
|
Directions to Hospitals Treating Cryptogenic organizing pneumonitis |
|
Risk calculators and risk factors for Cryptogenic organizing pneumonia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Medical Therapy
About two-thirds of patients recover with corticosteroid therapy. Prednisolone is often administered in Europe and prednisone in the USA. These two compounds differ by only one functional group and have the same clinical effect. The steroid is initially administered at high doses, typically 50 mg per day tapering down to zero over a 6 month to one year period. If the steroid treatment is halted too quickly the disease may return.